CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions

Hong Yue Lai, Ling Wei Hsu, Hsin Hwa Tsai, Yu-Chih Lo, Shang-Hsun Yang, Ping-Yen Liu, Ju-Ming Wang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims Lipid homeostasis is reprogrammed in the presence of inflammation, which results in excessive lipid accumulation in macrophages, and leads to the formation of lipid–laden foam cells. We aimed to link an inflammation-responsive transcription factor CCAAT/enhancer-binding protein delta (CEBPD) with polarized macrophages and dissect its contribution to lipid accumulation. Methods We found that CEBPD protein colocalized with macrophages in human and mouse (C57BL/6, Apoe/-) atheroscler- and results otic plaques and that Cebpd deficiency in bone marrow cells suppressed atherosclerotic lesions in hyperlipidemic Apoe/- mice. CEBPD was responsive to modified low-density lipoprotein (LDL) via the p38MAPK/CREB pathway, and it promoted lipid accumulation in M1 macrophages but not in M2 macrophages. CEBPD up-regulated pentraxin 3 (PTX3), which promoted the macropinocytosis of LDL, and down-regulated ATP-binding cassette subfamily A member 1 (ABCA1), which impaired the intracellular cholesterol efflux in M1 macrophages. We further found that simvastatin (a HMG–CoA reductase inhibitor) could target CEBPD to block lipid accumulation in a manner not directly related to its cholesterol-lowering effect in M1 macrophages. Conclusion This study underscores how CEBPD functions at the junction of inflammation and lipid accumulation in M1 macrophages. Therefore, CEBPD-mediated lipid accumulation in M1 macrophages could represent a new therapeutic target for the treatment of cardiovascular diseases.

Original languageEnglish
Pages (from-to)1376-1388
Number of pages13
JournalCardiovascular Research
Volume113
Issue number11
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

CCAAT-Enhancer-Binding Protein-delta
Blood Vessels
Macrophages
Lipids
Apolipoproteins E
Inflammation
LDL Lipoproteins
Cholesterol
Foam Cells
Simvastatin
Inbred C57BL Mouse
Bone Marrow Cells
Ear
Oxidoreductases
Homeostasis
Transcription Factors
Cardiovascular Diseases
Adenosine Triphosphate

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

@article{df205f3cdb064c279a53cbcefb03c155,
title = "CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions",
abstract = "Aims Lipid homeostasis is reprogrammed in the presence of inflammation, which results in excessive lipid accumulation in macrophages, and leads to the formation of lipid–laden foam cells. We aimed to link an inflammation-responsive transcription factor CCAAT/enhancer-binding protein delta (CEBPD) with polarized macrophages and dissect its contribution to lipid accumulation. Methods We found that CEBPD protein colocalized with macrophages in human and mouse (C57BL/6, Apoe/-) atheroscler- and results otic plaques and that Cebpd deficiency in bone marrow cells suppressed atherosclerotic lesions in hyperlipidemic Apoe/- mice. CEBPD was responsive to modified low-density lipoprotein (LDL) via the p38MAPK/CREB pathway, and it promoted lipid accumulation in M1 macrophages but not in M2 macrophages. CEBPD up-regulated pentraxin 3 (PTX3), which promoted the macropinocytosis of LDL, and down-regulated ATP-binding cassette subfamily A member 1 (ABCA1), which impaired the intracellular cholesterol efflux in M1 macrophages. We further found that simvastatin (a HMG–CoA reductase inhibitor) could target CEBPD to block lipid accumulation in a manner not directly related to its cholesterol-lowering effect in M1 macrophages. Conclusion This study underscores how CEBPD functions at the junction of inflammation and lipid accumulation in M1 macrophages. Therefore, CEBPD-mediated lipid accumulation in M1 macrophages could represent a new therapeutic target for the treatment of cardiovascular diseases.",
author = "Lai, {Hong Yue} and Hsu, {Ling Wei} and Tsai, {Hsin Hwa} and Yu-Chih Lo and Shang-Hsun Yang and Ping-Yen Liu and Ju-Ming Wang",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/cvr/cvx134",
language = "English",
volume = "113",
pages = "1376--1388",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "11",

}

CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions. / Lai, Hong Yue; Hsu, Ling Wei; Tsai, Hsin Hwa; Lo, Yu-Chih; Yang, Shang-Hsun; Liu, Ping-Yen; Wang, Ju-Ming.

In: Cardiovascular Research, Vol. 113, No. 11, 01.01.2017, p. 1376-1388.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions

AU - Lai, Hong Yue

AU - Hsu, Ling Wei

AU - Tsai, Hsin Hwa

AU - Lo, Yu-Chih

AU - Yang, Shang-Hsun

AU - Liu, Ping-Yen

AU - Wang, Ju-Ming

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aims Lipid homeostasis is reprogrammed in the presence of inflammation, which results in excessive lipid accumulation in macrophages, and leads to the formation of lipid–laden foam cells. We aimed to link an inflammation-responsive transcription factor CCAAT/enhancer-binding protein delta (CEBPD) with polarized macrophages and dissect its contribution to lipid accumulation. Methods We found that CEBPD protein colocalized with macrophages in human and mouse (C57BL/6, Apoe/-) atheroscler- and results otic plaques and that Cebpd deficiency in bone marrow cells suppressed atherosclerotic lesions in hyperlipidemic Apoe/- mice. CEBPD was responsive to modified low-density lipoprotein (LDL) via the p38MAPK/CREB pathway, and it promoted lipid accumulation in M1 macrophages but not in M2 macrophages. CEBPD up-regulated pentraxin 3 (PTX3), which promoted the macropinocytosis of LDL, and down-regulated ATP-binding cassette subfamily A member 1 (ABCA1), which impaired the intracellular cholesterol efflux in M1 macrophages. We further found that simvastatin (a HMG–CoA reductase inhibitor) could target CEBPD to block lipid accumulation in a manner not directly related to its cholesterol-lowering effect in M1 macrophages. Conclusion This study underscores how CEBPD functions at the junction of inflammation and lipid accumulation in M1 macrophages. Therefore, CEBPD-mediated lipid accumulation in M1 macrophages could represent a new therapeutic target for the treatment of cardiovascular diseases.

AB - Aims Lipid homeostasis is reprogrammed in the presence of inflammation, which results in excessive lipid accumulation in macrophages, and leads to the formation of lipid–laden foam cells. We aimed to link an inflammation-responsive transcription factor CCAAT/enhancer-binding protein delta (CEBPD) with polarized macrophages and dissect its contribution to lipid accumulation. Methods We found that CEBPD protein colocalized with macrophages in human and mouse (C57BL/6, Apoe/-) atheroscler- and results otic plaques and that Cebpd deficiency in bone marrow cells suppressed atherosclerotic lesions in hyperlipidemic Apoe/- mice. CEBPD was responsive to modified low-density lipoprotein (LDL) via the p38MAPK/CREB pathway, and it promoted lipid accumulation in M1 macrophages but not in M2 macrophages. CEBPD up-regulated pentraxin 3 (PTX3), which promoted the macropinocytosis of LDL, and down-regulated ATP-binding cassette subfamily A member 1 (ABCA1), which impaired the intracellular cholesterol efflux in M1 macrophages. We further found that simvastatin (a HMG–CoA reductase inhibitor) could target CEBPD to block lipid accumulation in a manner not directly related to its cholesterol-lowering effect in M1 macrophages. Conclusion This study underscores how CEBPD functions at the junction of inflammation and lipid accumulation in M1 macrophages. Therefore, CEBPD-mediated lipid accumulation in M1 macrophages could represent a new therapeutic target for the treatment of cardiovascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=85048946558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048946558&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvx134

DO - 10.1093/cvr/cvx134

M3 - Article

VL - 113

SP - 1376

EP - 1388

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 11

ER -